Table 2 Intervention characteristics and individual characteristics
Baseline, % | Follow-up, % | ||||||||
|---|---|---|---|---|---|---|---|---|---|
n | Strongly disagree/Disagree | Neither Agree or Disagree | Strongly agree/Agree | n | Strongly disagree/Disagree | Neither Agree or Disagree | Strongly agree/Agree | p-valued | |
Intervention Characteristics | |||||||||
Delivering medications (buprenorphine or naltrexone) to treat OUD in my clinic: | |||||||||
Is important | 54 | 1.8 | 0.0 | 94.7 | 57 | 1.6 | 4.9 | 86.9 | 0.16 |
Will save livesb | 54 | 0.0 | 3.6 | 92.8 | 57 | 0.0 | 4.9 | 88.5 | 0.39 |
Is time consumingb | 52 | 28.6 | 26.8 | 37.5 | 57 | 26.2 | 32.8 | 34.5 | 0.66 |
Detracts from my clinical responsibilities | 53 | 50.7 | 19.6 | 14.3 | 56 | 52.5 | 24.6 | 14.8 | 0.87 |
Is more dangerous than management of other chronic conditionsb | 53 | 67.8 | 10.7 | 16.1 | 57 | 68.9 | 18.0 | 6.6 | 0.10 |
Is supported by randomized clinical trials or other scientific evidencea | 54 | 1.9 | 13.0 | 85.2 | 57 | 1.8 | 8.8 | 89.5 | 0.60 |
Is consistent with clinical practices that have been accepted by VA patientsa | 54 | 3.7 | 11.1 | 85.2 | 57 | 3.5 | 19.3 | 78.2 | 0.20 |
Can be integrated into my clinic’s procedures and workflowa | 54 | 7.1 | 14.3 | 75.0 | 56 | 8.2 | 14.8 | 68.9 | 0.64 |
Individual Characteristics | |||||||||
Indicate your level of agreement or disagreement with the following statements: | |||||||||
The risk of patients diverting these medications is too highc | 54 | 64.8 | 22.2 | 13.0 | 58 | 56.9 | 32.8 | 10.3 | 0.76 |